The invention discloses a recombinant
carbonyl reductase sourced from
Burkholderia gladioli ZJB-12126 as well as an encoding
gene of the recombinant
carbonyl reductase, a recombinant vector containing the
gene, a recombinant
gene engineering bacterium obtained by transforming the recombinant vector, and an application of the recombinant
carbonyl reductase in asymmetrically reducing prochiral carbonyl compounds. According to the recombinant carbonyl
reductase disclosed by the invention, by respectively taking 2-benzamidomethyl-3-
ketone butyrate, 4-chloroacetoacetic acid
ethyl ester (COBE), (R)-6-cyano-5-hydroxyl-3-carbonyl caproate tert-butyl ester and (4S)-3-[5-(4-fluorophenyl)-1,5-dioxopentyl]-4-phenyl-2-oxazolidinone as substrates, (2S, 3R)-2-benzamidomethyl-3-
polyhydroxybutyrate, (S)-4-chloro-3-ethyl hydroxybutyrate, 6-cyano-(3R, 5R)-dihydroxyhexanoic acid tert-butyl ester and (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxyl valeryl]-4-phenyl-1,3-oxo-azacyclopentane-2-
ketone with high optical purity are prepared by virtue of biocatalytic reaction, wherein the biocatalytic reaction can be performed by using
recombinant escherichia coli as a biocatalyst, and thus optional new
enzyme sources can be provided for biocatalytic synthesis of chiral intermediates of medicines.